[Locally advanced non-small cell lung cancer]

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Research

Background:

• Stages III A and III B lung cancer without pleural effusion present a complex treatment challenge.
• High prevalence (at least 80%) of micrometastatic disease at diagnosis indicates systemic involvement.
• Exclusive reliance on local treatment strategies is insufficient for effective disease control.

Purpose of the Study:

• To define the objectives for treating stages III A and III B lung cancer without pleural effusion.
• To emphasize the necessity of addressing both locoregional and distant disease control.
• To highlight the ongoing need for clinical research in managing advanced lung cancer.

Main Methods:

• This study is a conceptual analysis based on established knowledge of lung cancer progression.
• It reviews the implications of micrometastatic disease on treatment efficacy.
• Focuses on the strategic goals for locoregional and distant disease management.

Main Results:

• Locoregional and distant disease control are essential objectives for stages III A and III B lung cancer.
• The presence of widespread micrometastatic disease renders purely local treatments inadequate.
• Treatment failure is highly probable with approaches that do not account for systemic spread.

Conclusions:

• Effective management of stages III A and III B lung cancer necessitates a dual approach targeting both local and distant disease.
• The high incidence of micrometastatic disease underscores the limitations of solely local therapies.
• Further clinical research is crucial to navigate the diagnostic and therapeutic dilemmas in advanced lung cancer management.